Advertisement

CNS Leukemia

  • Yi An
  • Kenneth B. RobertsEmail author
Chapter

Abstract

Pediatric acute lymphoblastic leukemia (ALL) is the most common cancer of children and now has a particularly high cure rate as there have been improvements in risk stratification, matching the intensity of therapy to prognostic factors. These factors include risk for central nervous system (CNS) involvement, immunophenotype, molecular factors, and response to induction systemic therapy. Radiotherapy (RT) to treat the CNS due to relatively poorer penetration of chemotherapy through the physiologic blood–brain barrier had an important historical role in the development of ALL therapy. But use of RT in this role has been curtailed to high-risk patients in order to limit late occurring toxicities. The other uses of RT for AML include CNS relapse, palliative therapy, and total body irradiation as part of an allogeneic stem cell transplant. Radiotherapy is used in as similar albeit even less frequently for acute myeloid leukemias (AML) and related CNS lymphomas.

Keywords

Acute lymphoblastic leukemia Prophylactic cranial irradiation 

References

  1. Aur RJ, Hustu HO, Verzosa MS, Wood A, Simone JV (1973) Comparison of two methods of preventing central nervous system leukemia. Blood 42(3):349–357PubMedGoogle Scholar
  2. Birkebaek NH, Fisker S, Clausen N, Tuovinen V, Sindet-Pedersen S, Christiansen JS (1998) Growth and endocrinological disorders up to 21 years after treatment for acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 30(6):351–356CrossRefPubMedGoogle Scholar
  3. Bleyer WA (1981) Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 65(suppl 1):89–98PubMedGoogle Scholar
  4. Bleyer WA, Sather H, Hammond GD (1986) Prognosis and treatment after relapse of acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: 1985. A report from the Childrens Cancer Study Group. Cancer 58(2 suppl):590–594CrossRefPubMedGoogle Scholar
  5. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor AJ, Trigg ME, Children’s Cancer Group (2003) Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 101(10):3809–3817. doi: 10.1182/blood-2002-08-2454 CrossRefPubMedGoogle Scholar
  6. Buhrer C, Henze G, Hofmann J, Reiter A, Schellong G, Riehm H (1990) Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials. Haematol Blood Transfus 33:500–503PubMedGoogle Scholar
  7. Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, Borowitz MJ, Camitta BM, Carroll AJ, Devidas M, Pullen DJ, Payne-Turner D, Tasian SK, Reshmi S, Cottrell CE, Reaman GH, Bowman WP, Carroll WL, Loh ML, Winick NJ, Hunger SP, Willman CL (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 119(15):3512–3522. doi: 10.1182/blood-2011-11-394221 CrossRefPubMedPubMedCentralGoogle Scholar
  8. Cherlow JM, Sather H, Steinherz P, Gaynon P, Tubergen D, Trigg M, Novak L, Bleyer WA (1996) Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children’s Cancer Group. Int J Radiat Oncol Biol Phys 36(1):19–27CrossRefPubMedGoogle Scholar
  9. Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, Richards S, Childhood ALLCG (2003) CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 21(9):1798–1809. doi: 10.1200/JCO.2003.08.047 CrossRefPubMedGoogle Scholar
  10. Conter V, Schrappe M, Arico M, Reiter A, Rizzari C, Dordelmann M, Valsecchi MG, Zimmermann M, Ludwig WD, Basso G, Masera G, Riehm H (1997) Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster groups. J Clin Oncol 15(8):2786–2791CrossRefPubMedGoogle Scholar
  11. Creutzig U, Ritter J, Zimmermann M, Schellong G (1993) Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol 11(2):279–286CrossRefPubMedGoogle Scholar
  12. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Ritter J, Sander A, Schrauder A, von Stackelberg A, Stary J, Reinhardt D (2013) Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 122(1):37–43. doi: 10.1182/blood-2013-02-484097 CrossRefPubMedGoogle Scholar
  13. Dahl GV, Simone JV, Hustu HO, Mason C (1978) Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer 42(5):2187–2192CrossRefPubMedGoogle Scholar
  14. Dorge P, Meissner B, Zimmermann M, Moricke A, Schrauder A, Bouquin JP, Schewe D, Harbott J, Teigler-Schlegel A, Ratei R, Ludwig WD, Koehler R, Bartram CR, Schrappe M, Stanulla M, Cario G (2013) IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 98(3):428–432. doi: 10.3324/haematol.2011.056135 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Ferro A, Jabbour SK, Taunk NK, Aisner J, Cohler A, Somalya S, Goyal S (2014) Cranial irradiation in adults diagnosed with acute myelogenous leukemia presenting with hyperleukocytosis and neurologic dysfunction. Leuk Lymphoma 55(1):105–109. doi: 10.3109/10428194.2013.797088 CrossRefPubMedGoogle Scholar
  16. Freeman JE, Johnston PG, Voke JM (1973) Somnolence after prophylactic cranial irradiation in children with acute lymphoblastic leukaemia. Br Med J 4(5891):523–525CrossRefPubMedPubMedCentralGoogle Scholar
  17. Gajjar A, Harrison PL, Sandlund JT, Rivera GK, Ribeiro RC, Rubnitz JE, Razzouk B, Relling MV, Evans WE, Boyett JM, Pui CH (2000) Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 96(10):3381–3384PubMedGoogle Scholar
  18. Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Reaman GH, Sather HN, Steinherz PG, Trigg ME, Tubergen DG, Uckun FM (1997) Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 80(9):1717–1726CrossRefPubMedGoogle Scholar
  19. Goshen Y, Stark B, Kornreich L, Michowiz S, Feinmesser M, Yaniv I (2007) High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 49(3):294–297. doi: 10.1002/pbc.21153 CrossRefPubMedGoogle Scholar
  20. Greydanus DE, Burgert EO Jr, Gilchrist GS (1978) Hypothalamic syndrome in children with acute lymphocytic leukemia. Mayo Clin Proc 53(4):217–220PubMedGoogle Scholar
  21. Griffin TW, Rasey JS, Bleyer WA (1977) The effect of photon irradiation on blood-brain barrier permeability to methotrexate in mice. Cancer 40(3):1109–1111CrossRefPubMedGoogle Scholar
  22. Halberg FE, Kramer JH, Moore IM, Wara WM, Matthay KK, Ablin AR (1992) Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 22(1):13–16CrossRefPubMedGoogle Scholar
  23. Halsey C, Buck G, Richards S, Vargha-Khadem F, Hill F, Gibson B (2011) The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol 4:42. doi: 10.1186/1756-8722-4-42 CrossRefPubMedPubMedCentralGoogle Scholar
  24. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE, Sandlund JT, Rivera GK, Evans WE, Relling MV, Pui CH (2007) Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297(11):1207–1215. doi: 10.1001/jama.297.11.1207 CrossRefPubMedGoogle Scholar
  25. Hill JM, Kornblith AB, Jones D, Freeman A, Holland JF, Glicksman AS, Boyett JM, Lenherr B, Brecher ML, Dubowy R, Kung F, Maurer H, Holland JC (1998) A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 82(1):208–218CrossRefPubMedGoogle Scholar
  26. Hiniker SM, Agarwal R, Modlin LA, Gray CC, Harris JP, Million L, Kiamanesh EF, Donaldson SS (2014) Survival and neurocognitive outcomes after cranial or craniospinal irradiation plus total-body irradiation before stem cell transplantation in pediatric leukemia patients with central nervous system involvement. Int J Radiat Oncol Biol Phys 89(1):67–74. doi: 10.1016/j.ijrobp.2014.01.056 CrossRefPubMedGoogle Scholar
  27. Hong JH, Chiang CS, Campbell IL, Sun JR, Withers HR, McBride WH (1995) Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys 33(3):619–626. doi: 10.1016/0360-3016(95)00279-8 CrossRefPubMedGoogle Scholar
  28. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 30(14):1663–1669. doi: 10.1200/JCO.2011.37.8018 CrossRefPubMedPubMedCentralGoogle Scholar
  29. Jankovic M, Brouwers P, Valsecchi MG, Van Veldhuizen A, Huisman J, Kamphuis R, Kingma A, Mor W, Van Dongen-Melman J, Ferronato L et al (1994) Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet 344(8917):224–227CrossRefPubMedGoogle Scholar
  30. Jones B, Freeman AI, Shuster JJ, Jacquillat C, Weil M, Pochedly C, Sinks L, Chevalier L, Maurer HM, Koch K et al (1991) Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19(4):269–275CrossRefPubMedGoogle Scholar
  31. Keime-Guibert F, Napolitano M, Delattre JY (1998) Neurological complications of radiotherapy and chemotherapy. J Neurol 245(11):695–708CrossRefPubMedGoogle Scholar
  32. Kumar P, Kun LE, Hustu HO, Mulhern RK, Hancock ML, Coffey D, Rivera GK (1995) Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 31(3):477–483. doi: 10.1016/0360-3016(94)00344-K CrossRefPubMedGoogle Scholar
  33. Kun LE, Camitta BM, Mulhern RK, Lauer SJ, Kline RW, Casper JT, Kamen BA, Kaplan BM, Barber SW (1984) Treatment of meningeal relapse in childhood acute lymphoblastic leukemia. I. Results of craniospinal irradiation. J Clin Oncol 2(5):359–364CrossRefPubMedGoogle Scholar
  34. Land VJ, Thomas PR, Boyett JM, Glicksman AS, Culbert S, Castleberry RP, Berry DH, Vats T, Humphrey GB (1985) Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia. A Pediatric Oncology Group study. Cancer 56(1):81–87CrossRefPubMedGoogle Scholar
  35. Laver JH, Barredo JC, Amylon M, Schwenn M, Kurtzberg J, Camitta BM, Pullen J, Link MP, Borowitz M, Ravindranath Y, Murphy SB, Shuster J (2000) Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. Leukemia 14(3):369–373CrossRefPubMedGoogle Scholar
  36. Littman P, Rosenstock J, Gale G, Krisch RE, Meadows A, Sather H, Coccia P, DeCamargo B (1984) The somnolence syndrome in leukemic children following reduced daily dose fractions of cranial radiation. Int J Radiat Oncol Biol Phys 10(10):1851–1853CrossRefPubMedGoogle Scholar
  37. Mahoney DH Jr, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, Camitta B (1998) Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol 16(1):246–254CrossRefPubMedGoogle Scholar
  38. Mandell LR, Walker RW, Steinherz P, Fuks Z (1989) Reduced incidence of the somnolence syndrome in leukemic children with steroid coverage during prophylactic cranial radiation therapy. Results of a pilot study. Cancer 63(10):1975–1978CrossRefPubMedGoogle Scholar
  39. Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Revesz T, Alvaro F, Suppiah R, Norris MD, Pieters R (2013) High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia 27(7):1497–1503. doi: 10.1038/leu.2013.44 CrossRefPubMedGoogle Scholar
  40. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, Loning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M, German-Austrian-Swiss ALLBFMSG (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111(9):4477–4489. doi: 10.1182/blood-2007-09-112920 CrossRefPubMedGoogle Scholar
  41. Morra E, Lazzarino M, Brusamolino E, Pagnucco G, Castagnola C, Bernasconi P, Orlandi E, Corso A, Santagostino A, Bernasconi C (1993) The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. Cancer 72(2):439–445CrossRefPubMedGoogle Scholar
  42. Mulhern RK, Fairclough D, Ochs J (1991) A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol 9(8):1348–1356CrossRefPubMedGoogle Scholar
  43. Neglia JP, Meadows AT, Robison LL, Kim TH, Newton WA, Ruymann FB, Sather HN, Hammond GD (1991) Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325(19):1330–1336. doi: 10.1056/NEJM199111073251902 CrossRefPubMedGoogle Scholar
  44. Nesbit ME, Ertel I, Hammond GD (1981) L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group. Cancer Treat Rep 65(suppl 4):101–107PubMedGoogle Scholar
  45. Nesbit ME, Sather H, Robison LL, Donaldson M, Littman P, Ortega JA, Hammond GD (1982) Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: a report from Children’s Cancer Study Group. Cancer Res 42(2):674–680PubMedGoogle Scholar
  46. Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T (2015) Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol 33(11):1265–1274. doi: 10.1200/JCO.2014.58.9747 CrossRefPubMedGoogle Scholar
  47. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360(26):2730–2741. doi: 10.1056/NEJMoa0900386 CrossRefPubMedPubMedCentralGoogle Scholar
  48. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, Rubnitz JE, Razzouk BI, Howard SC, Hudson MM, Cheng C, Kun LE, Raimondi SC, Behm FG, Downing JR, Relling MV, Evans WE, Total Therapy Study XIIIB at St Jude Children's Research Hospital (2004) Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood 104(9):2690–2696. doi: 10.1182/blood-2004-04-1616 CrossRefPubMedGoogle Scholar
  49. Ribeiro RC, Rivera GK, Hudson M, Mulhern RK, Hancock ML, Kun L, Mahmoud H, Sandlund JT, Crist WM, Pui CH (1995) An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 13(2):333–338CrossRefPubMedGoogle Scholar
  50. Rieselbach RE, Di Chiro G, Freireich EJ, Rall DP (1962) Subarachnoid distribution of drugs after lumbar injection. N Engl J Med 267:1273–1278. doi: 10.1056/NEJM196212202672502 CrossRefPubMedGoogle Scholar
  51. Ritchey AK, Pollock BH, Lauer SJ, Andejeski Y, Barredo J, Buchanan GR (1999) Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study. J Clin Oncol 17(12):3745–3752CrossRefPubMedGoogle Scholar
  52. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE (1994) Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children’s Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12(4):740–747CrossRefPubMedGoogle Scholar
  53. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E (2000a) Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 14(12):2193–2194CrossRefPubMedGoogle Scholar
  54. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H (2000b) Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95(11):3310–3322PubMedGoogle Scholar
  55. Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293(4):161–166. doi: 10.1056/NEJM197507242930402 CrossRefPubMedGoogle Scholar
  56. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi: 10.3322/caac.21208 CrossRefPubMedGoogle Scholar
  57. Simone JV (1981) Optimal current treatment of childhood acute lymphoblastic leukemia. Cancer Treat Rep 65(suppl 4):97–100PubMedGoogle Scholar
  58. Sirvent N, Suciu S, Rialland X, Millot F, Benoit Y, Plantaz D, Ferster A, Robert A, Lutz P, Nelken B, Plouvier E, Norton L, Bertrand Y, Otten J (2011) Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881. Eur J Cancer 47(2):239–247. doi: 10.1016/j.ejca.2010.10.019 CrossRefPubMedGoogle Scholar
  59. Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, Gonzalez A, Izraeli S, Janic D, Jazbec J, Konja J, Kaiserova E, Kowalczyk J, Kovacs G, Li CK, Magyarosy E, Popa A, Stark B, Jabali Y, Trka J, Hrusak O, Riehm H, Masera G, Schrappe M (2014) Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol 32(3):174–184. doi: 10.1200/JCO.2013.48.6522 CrossRefPubMedGoogle Scholar
  60. Steffens M, Beauloye V, Brichard B, Robert A, Alexopoulou O, Vermylen C, Maiter D (2008) Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf) 69(5):819–827. doi: 10.1111/j.1365-2265.2008.03283.x CrossRefGoogle Scholar
  61. Stubberfield TG, Byrne GC, Jones TW (1995) Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation. J Pediatr Hematol Oncol 17(2):167–171CrossRefPubMedGoogle Scholar
  62. Uzal D, Ozyar E, Hayran M, Zorlu F, Atahan L, Yetkin S (1998) Reduced incidence of the somnolence syndrome after prophylactic cranial irradiation in children with acute lymphoblastic leukemia. Radiother Oncol 48(1):29–32CrossRefPubMedGoogle Scholar
  63. van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML (2013) Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122(15):2622–2629. doi: 10.1182/blood-2012-10-462358 CrossRefPubMedPubMedCentralGoogle Scholar
  64. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352(9142):1731–1738. doi: 10.1016/S0140-6736(98)04058-6 CrossRefPubMedGoogle Scholar
  65. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bokkerink JP, Bruin MC, van den Heuvel-Eibrink MM, Korbijn CM, Korthof ET, van der Pal K, Stijnen T, van Weel Sipman MH, van Weerden JF, van Wering ER, van der Does-van den Berg A, Dutch Childhood Oncology G (2009) Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 10(10):957–966. doi: 10.1016/S1470-2045(09)70228-1 CrossRefPubMedGoogle Scholar
  66. Waber DP, Shapiro BL, Carpentieri SC, Gelber RD, Zou G, Dufresne A, Romero I, Tarbell NJ, Silverman LB, Sallan SE (2001) Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer 92(1):15–22CrossRefPubMedGoogle Scholar
  67. Waber DP, Tarbell NJ, Fairclough D, Atmore K, Castro R, Isquith P, Lussier F, Romero I, Carpenter PJ, Schiller M et al (1995) Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. J Clin Oncol 13(10):2490–2496CrossRefPubMedGoogle Scholar
  68. Waber DP, Turek J, Catania L, Stevenson K, Robaey P, Romero I, Adams H, Alyman C, Jandet-Brunet C, Neuberg DS, Sallan SE, Silverman LB (2007) Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol 25(31):4914–4921. doi: 10.1200/JCO.2007.10.8464 CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Therapeutic RadiologyYale University School of MedicineNew HavenUSA

Personalised recommendations